**7. Conclusions**

Utilising VLPs as vaccine constructs provides flexibility and many prospects in design that can significantly enhance protection and immunogenicity. IL-13 represents an excellent proof-of-concept target to validate anti-cytokine vaccination as a therapeutic strategy in humans based on validated vaccine targets, an excellent target safety profile, and broad vaccine applicability. Treating IL-13-related immunological disorders with a therapeutic vaccine will offer a new avenue in medical intervention.

**Author Contributions:** J.F. and A.M. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was not supported by external funding.

**Acknowledgments:** The authors would like to acknowledge the support of Jean-Christophe Bourdon in the co-supervision of AM research.

**Conflicts of Interest:** J.F. is co-owner and CEO of a commercial company (www.healvax.com) that holds licence rights for the clinical development of IL-13 targeting vaccines. Healvax had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
